检索历史 清除

目的:系统评价贝伐珠单抗联合FOLFOX方案治疗进展期结直肠癌的临床疗效和安全性。方法:以"Bevacizumab、FOLFOX、Advanced Colorectal Cancer、Randomized Controlled Trial"为英文检索词，以"贝伐珠单抗、FOLFOLX、进展期结直肠癌、随机对照试验"为中文检索词，计算机检索Pubmed、EMBSE、中国知网等中英文数据库从建库到2018年12月的相关文献，按照治疗方法分为联合组(贝伐珠单抗联合FOLFOX方案)和对照组(单独使用FOLFOX方案)，使用Revman5.3软件进行Meta分析。结果:本研究最终纳入11篇相关的随机对照研究，样本量为3178例，其中联合组1599例，对照组1579例。Meta分析结果显示，联合组客观缓解率( OR＝3.15，95% CI：2.25～4.40, Z＝6.71， P<0.000 01)和疾病控制率( OR ＝2.73, 95% CI：1.91～3.90, Z＝5.49， P<0.000 1)均高于对照组，在不良反应方面，联合组胃肠道反应发生率高于对照组( OR＝1.29，95% CI：1.07～1.55， Z＝2.64， P＝0.008)，肝损伤、白细胞减低、高血压、神经毒性等发生率两组间差异无统计学意义。 结论:贝伐珠单抗联合FOLFOX方案治疗进展期结直肠癌较单纯FOLFOX方案更加有效，但会增加胃肠道反应的发生风险。

Objective:To systematically evaluate the clinical effect and safety of bevacizumab combined with FOLFOX regimen in patients with advanced colorectal cancer.Methods:An electronic search of Pubmed, Embase, CNKI and other Chinese and English databases were retried from their inception to December 2018 to identify relevant literatures, by taking "Bevacizumab, FOLFOX, Advanced Colorectal Cancer, Randomized Controlled Trial" as the keywords for retrieval. Patients were divided into a combination group (bevacizumab combined with FOLFOX program) and a control group (using FOLFOX program alone) according to the treatment method, using Revman 5.3 software for meta-analysis.Results:A total of 11 articles, involving 3178 patients, were included with 1599 in the combination group and 1579 in the control group. The objective group response rate ( OR=3.15, 95% CI: 2.25 ~ 4.40, Z=6.71, P<0.000 01) and disease control rate ( OR=2.73, 95% CI: 1.91 ~ 3.90, Z=5.49, P<0.000 1) in combination group were higher than those in the control group. In terms of adverse reactions, the incidence of gastrointestinal reactions in the combination group was higher than that in the control group ( OR=1.29, 95% CI: 1.07~1.55, Z=2.64, P=0.008 ), There was no significant difference in the incidence of liver injury, leukopenia, hypertension, and neurotoxicity between the two groups. Conclusion:Bevacizumab combined with FOLFOX regimen is more effective than FOLFOX regimen for patients with advanced colorectal cancer, but it will increase the risk of gastrointestinal reactions.